Literature DB >> 3932300

Evolution and epidemiology of MLS resistance.

J Duval.   

Abstract

Within the framework of this symposium, it is not feasible to present an exhaustive description of the present state of knowledge regarding the sensitivity and resistance of bacterial species to macrolides, lincosamides and streptogramins (MLS). This paper is limited to a description of the evolution of different types of resistance in the light of decisive factors described in previous papers, in order to deduce, if at all possible, trends in future strategy in therapeutics. Only acquired resistance lends itself to epidemiological study, in contrast to natural resistance which is, by definition, characteristic of a species or a genus, and not liable to change. Three groups will therefore be studied in turn: Staphylococcus aureus, streptococci and Bacteroides fragilis. There is as yet insufficient accumulated data to draw conclusions regarding the epidemiology and evolution of MLSB resistance observed in Clostridium perfringens and Corynebacterium diphtheriae, or regarding the high-level resistance to erythromycin due to enzymatic inactivation recently described in Escherichia coli.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932300     DOI: 10.1093/jac/16.suppl_a.137

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

Review 1.  Mechanisms of antimicrobial resistance: their clinical relevance in the new millennium.

Authors:  Armine M Sefton
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci.

Authors:  G Lina; A Quaglia; M E Reverdy; R Leclercq; F Vandenesch; J Etienne
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  Update on the major clonal types of methicillin-resistant Staphylococcus aureus in the Czech Republic.

Authors:  O Melter; M Aires de Sousa; P Urbásková; V Jakubů; H Zemlicková; H de Lencastre
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

Review 4.  Formulary management of macrolide antibiotics.

Authors:  D R Guay
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

5.  Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital.

Authors:  A B Reid; J R Daffy; P Stanley; K L Buising
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

6.  Lack of emergence of significant resistance in vitro and in vivo to the new azalide antibiotic azithromycin.

Authors:  J A Retsema; A E Girard; L A Brennan; C R Cimochowski; J A Faiella
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-10       Impact factor: 3.267

Review 7.  Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria.

Authors:  R Leclercq; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

8.  Naturally occurring Staphylococcus epidermidis plasmid expressing constitutive macrolide-lincosamide-streptogramin B resistance contains a deleted attenuator.

Authors:  B C Lampson; J T Parisi
Journal:  J Bacteriol       Date:  1986-05       Impact factor: 3.490

9.  Characterization of erythromycin-resistant isolates of Staphylococcus aureus recovered in the United States from 1958 through 1969.

Authors:  F G Nicola; L K McDougal; J W Biddle; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.